Norman Kumins, MD
Vascular Surgery · Beachwood, OHNPI 1841266756
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.1% of the total across 195 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by Medtronic at 49.6% of the total. Reporting peaked in 2019 at $2,880 and has fallen 76.8% since, to $669 in 2025.
Across 195 payments — averaging $46.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$4K
- Shockwave Medical, Inc$2K
- Bolton Medical Inc$480
- Penumbra, Inc.$427
- Silk Road Medical, Inc.$341
- W. L. Gore & Associates, Inc.$328
- plus $994 from 19 others
Across 16 payments — averaging $4285.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bolton Medical Inc$69K
What the payments were for
- Consulting fees$7198%
- Food & beverage$8,34292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 108 | $4,498 |
| Shockwave Medical, Inc | 27 | $1,993 |
| Bolton Medical Inc | 6 | $480 |
| Penumbra, Inc. | 7 | $427 |
| Silk Road Medical, Inc. | 3 | $341 |
| W. L. Gore & Associates, Inc. | 4 | $328 |
| Boston Scientific | 6 | $277 |
| Organogenesis Inc. | 1 | $114 |
| Bard Peripheral Vascular, Inc. | 3 | $76 |
| Amgen | 5 | $66 |
| Pfizer | 5 | $66 |
| Stryker | 2 | $63 |
| Johnson & Johnson | 3 | $51 |
| Astellas Pharma US Inc | 2 | $40 |
| Surmodics, Inc. | 2 | $34 |
| Argon Medical Devices, Inc. | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 2 | $32 |
| Inari Medical, Inc. | 1 | $29 |
| Boehringer Ingelheim | 1 | $19 |
| Z-medica, LLC | 1 | $19 |
| Cook Medical LLC | 1 | $18 |
| Artivion, Inc. | 1 | $17 |
| Angiodynamics, Inc. | 1 | $15 |
| Lantheus Medical Imaging, Inc. | 1 | $14 |
| EKOS Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Endurant$1,243
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,209
- IN.PACT Admiral$382
- ENROUTE Transcarotid Neuroprotection System$302
- ENROUTE Transcarotid Stent$302
- Valiant Navion$285
- TREO ABDOMINAL STENT-GRAFT SYSTEM$266
- HawkOne$210
- TurboHawk$126
- VIABAHN VBX Balloon Expandable Endoprosthesis$125
- CareLink$121
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$119
- Relay Grafts$116
- Apligraf$114
- Penumbra System$109
How this compares
$9,061 in reported general payments places this provider in the 70th percentile of 213 vascular surgery providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 13 | $9,776 |
| Rosuvastatin Calcium | 47 | $1,028 |
| ClopidogrelClopidogrel Bisulfate | 57 | $870 |
| Atorvastatin Calcium | 30 | $801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $51 | $9,77613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 213 vascular surgery providers in Ohio.
Other vascular surgery in Beachwood
- Patrick MuckCincinnati$650K
- Sean LydenCleveland$561K
- Brian KuhnCincinnati$184K
- Vikram RaoWilloughby$137K
- Federico ParodiCleveland$78K
- Francis CaputoCleveland$75K
- Matthew RechtCincinnati$73K
- Geoffrey AnswiniCincinnati$65K
- John PigottToledo$65K
- Adam ReichardMontgomery$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.